glipizide has been researched along with metformin in 100 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.00) | 18.7374 |
| 1990's | 10 (10.00) | 18.2507 |
| 2000's | 35 (35.00) | 29.6817 |
| 2010's | 46 (46.00) | 24.3611 |
| 2020's | 6 (6.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fowler, LK | 1 |
| Madhavan, R; Sankaran, JR; Seshasaianam, C; Seshiah, V; Shanker, R; Sundaram, A; Venkataraman, S | 1 |
| Huupponen, R; Karvonen, I; Rytömaa, K; Sotaniemi, EA; Vierimaa, E; Vuoti, MJ | 1 |
| Barclay, SC; Gibson, J; Lamey, PJ; Miller, S | 1 |
| Brown, IR; Campbell, IW; McBain, AM; Menzies, DG | 1 |
| Ferlito, S; Lunetta, M; Mangiagli, P; Tranchida, ML | 1 |
| Chow, CC; Cockram, CS; Sorensen, JP; Tsang, LW | 1 |
| Chen, YD; Jeppesen, J; Reaven, GM; Zhou, MY | 1 |
| Anderson, D; Briscoe, TA; Cooper, GS; Usifo, OS | 1 |
| Abbasi, F; Carantoni, M; Chen, YD; Kamath, V; Reaven, GM; Rizvi, AA | 1 |
| André, P | 1 |
| Arocho, R; Botteman, MF; Grossman, JA; Ramsdell, JW; Stephens, JM | 1 |
| Kirk, JK; Michielutte, R; Pearce, KA; Summerson, JH | 1 |
| Goyal, RK; Maheshwari, S; Saxena, T | 1 |
| Ravi, J; Ravisankar, S; Suresh, B; Vasudevan, M | 1 |
| Bagg, W; Braatvedt, GD; Drury, PL; Gamble, G; Sharpe, N; Whalley, GA | 1 |
| Ertorer, EM; Gokcel, A; Guvener, N; Karakose, H; Tanaci, N; Tutuncu, NB | 1 |
| Bell-Farrow, AD; Cefalu, WT; Edwards, IJ; Terry, JG | 1 |
| Bell-Farrow, A; Carlson, HE; Cefalu, WT; Gan Lim, L; Izon, MP; Kapoor, A; Migdal, P; Schneider, DJ; Sobel, BE; Terry, JG | 1 |
| Rochester, CD; Samuel, J | 1 |
| Goldstein, BJ; Pans, M; Rubin, CJ | 1 |
| Bell, CF; Botteman, MF; Braunstein, SN; Devine, ST; Ramsdell, JW; Stephens, JM | 1 |
| Knudsen, LL | 1 |
| Aburuz, S; McElnay, J; Millership, J | 1 |
| Boudoulas, H; Osei, K; Schuster, DP; Sparks, EA; Stakos, DA; Wooley, CF | 1 |
| Canovatchel, W; Cefalu, W; Chaiken, R; Dailey, G; Feinglos, M; Kourides, I; Osei, K; Tayek, J | 1 |
| Guo, H; Li, W; Liu, H; Nie, S; Ouyang, D; Pan, W | 1 |
| Defang, O; Hong, G; Hui, L; Shufang, N; Wei, L; Weisan, P | 1 |
| Daly, FF; Little, M; Murray, L; Soderstrom, J | 1 |
| Bradley, JD; Geary, RS; Kwon, Y; van Lier, JJ; VanVliet, AA; Watanabe, T; Wedel, M | 1 |
| Ding, CG; Ge, QH; Ma, LL; Zhi, XJ; Zhou, Z | 1 |
| Meininger, G; Nauck, MA; Sheng, D; Stein, PP; Terranella, L | 1 |
| Elo, B; Govorko, D; Villano, CM; White, LA | 1 |
| Bussel, II; Felgner, J; Jafari, M; Khodayari, B; Mueller, LD; Rose, MR | 1 |
| Rönnemaa, T; Vähätalo, M; Viikari, J | 1 |
| Drucker, DJ; Goldberg, RB; Holman, R | 1 |
| Chen, XY; Song, B; Zhang, SQ; Zhao, XH; Zhong, DF | 1 |
| Halperin, F; Ingelfinger, JR; McMahon, GT | 1 |
| Mandal, U; Pal, TK | 1 |
| Krishnarajah, G; Lyu, R; Mavros, P; Vexiau, P; Yin, D | 1 |
| Mogensen, CE; Sadikot, SM | 1 |
| Amatruda, JM; Davies, MJ; Kaufman, KD; Nauck, M; Seck, T; Sheng, D; Stein, PP; Sunga, S | 1 |
| Eriksson, J; Gallwitz, B; Gause-Nilsson, I; Göke, B; Hellqvist, A | 1 |
| Afifi, FU; Hamdan, I; Kasabri, V | 1 |
| Patel, GN; Patel, HR; Patel, MM; Patel, RB | 1 |
| Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Seck, TL; Sisk, CM; Wang, H; Williams-Herman, DE | 1 |
| Del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, MA; Parikh, SJ; Rohwedder, K | 1 |
| Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Nutter, B; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS | 1 |
| Bergenheim, K; Duprat-Lomon, I; Erhardt, W; McEwan, P | 1 |
| Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS | 1 |
| Davies, MJ; Ferrante, SA; Goldstein, BJ; Kaufman, KD; Krobot, KJ; Meininger, GE; Seck, T; Williams-Herman, D | 1 |
| Deng, Y; Li, F; Li, N; Qin, F; Yu, J | 1 |
| Binz, TM; Neels, H; Schneider, S; Villani, N | 1 |
| Plosker, GL | 1 |
| Cui, L; Dong, Y; Hong, J; Lai, S; Li, H; Liu, C; Lv, A; Ning, G; Shen, J; Shen, W; Su, Q; Tang, W; Wang, D; Wang, W; Wu, G; Zhang, Y; Zhao, J; Zhou, Z; Zhu, D; Zou, D | 1 |
| Del Prato, S; Nauck, M | 1 |
| del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, M; Parikh, SJ; Rohwedder, K | 1 |
| Fleck, P; Rosenstock, J; Wilson, C | 1 |
| Eriksson, JG; Gallwitz, B; Gause-Nilsson, I; Göke, B; Hellqvist, Å | 1 |
| Boyko, EJ; Floyd, JS; Forsberg, CW; Moore, K; Riley, K; Smith, NL; Wheeler, S | 1 |
| Ackerman, RJ; Altshuler, D; Billings, LK; Chamarthi, B; Clish, CB; Davis, J; Deik, A; Fanelli, RR; Florez, JC; Gerszten, RE; Grant, RW; Hernandez, AM; Huang, C; Hudson, MS; Khan, SQ; Littleton, KR; Lo, J; McCarthy, RM; Rhee, EP; Stolerman, E; Taylor, A; Walford, GA; Wang, TJ; Warner, AS | 1 |
| Bi, Y; Cai, MY; Liang, J; Ma, JH; Miao, H; Peng, ZH; Tong, GY; Xin, B; Yang, HJ; Zhu, DL | 1 |
| Gong, Y; Lund, SS | 1 |
| Hong, J; Lai, S; Ning, G; Zhang, Y | 1 |
| Minervini, G; Mintz, ML | 1 |
| Derosa, G; Maffioli, P | 1 |
| Del Prato, S; Durán-García, S; Langkilde, AM; Nauck, MA; Parikh, SJ; Rohwedder, K; Sugg, J | 1 |
| Cui, L; Dong, Y; Hong, J; Hu, C; Lai, S; Li, H; Liu, C; Lv, A; Ning, G; Shen, J; Shen, W; Su, Q; Tang, W; Wang, D; Wang, W; Wu, G; Xu, G; Zeng, J; Zhang, Y; Zhao, J; Zhou, Z; Zhu, D; Zou, D | 1 |
| Camisasca, R; Del Prato, S; Fleck, P; Wilson, C | 1 |
| Khatu, S; Poojary, S | 1 |
| Bryzinski, B; Cook, W; Hirshberg, B; Minervini, G | 1 |
| Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A | 1 |
| Del Prato, S; Durán-Garcia, S; Maffei, L; Nauck, M; Parikh, S; Rohwedder, K; Theuerkauf, A | 1 |
| Ackerman, RJ; Barbato, C; Billings, LK; Bui, R; Chamarthi, B; Chen, L; Colomo, N; Davis, J; Fanelli, RR; Fernandez, M; Florez, JC; Garber, L; Goldfine, A; Grant, RW; Harden, M; Hernandez, AM; Huang, C; Huang, P; Hudson, MS; Kaur, V; Khan, SQ; Lanier, A; Littleton, KR; Lo, J; Manning, AK; McCarthy, RM; Moore, AF; Stolerman, ES; Taylor, A; Thomas, MK; Todd, JN; Walford, GA; Warner, AS; Wexler, D | 1 |
| Chaudhari, P; Del Prato, S; Fleck, P; Wilson, C | 1 |
| Adeshara, K; Tupe, R | 1 |
| Chen, Z; Gongol, B; Lei, T; Li, Z; Marin, TL; Shang, F; Shyy, JY; Wang, Y; Xiao, H; Yin, Y; Zhang, J; Zhang, YY | 1 |
| El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MA | 1 |
| Chen, T; Jing, H; Pan, H; Pan, W; Yang, X | 1 |
| Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z | 1 |
| Chamarthi, B; Chen, L; Florez, JC; Goldfine, A; Hudson, M; Kaur, V; Littleton, KR; Manning, AK; Merino, J; Srinivasan, S; Thomas, MK | 1 |
| Cordiner, RLM; Pearson, ER | 1 |
| Chiriac, FL; Iancu, VI; Radu, GL; Scutariu, RE | 1 |
| Bilker, WB; Brensinger, CM; Flory, JH; Hee Nam, Y; Hennessy, S; Leonard, CE | 1 |
| Abdallah, FF; Abdelaleem, EA; Emam, AA; Magdy, F | 1 |
| Abdul-Ghani, MA; Adams, AC; Adams, J; Cersosimo, E; Cheng, CC; DeFronzo, RA; Fourcaudot, M; Heikkinen, S; Khattab, A; Norton, L; Puckett, C; Samms, RJ; Triplitt, C; Tsintzas, K | 1 |
| Heinla, K; Johannson, A; Katus, U; Rünkorg, K; Toompere, K; Uusküla, A; Volke, V | 1 |
| Gayakvad, B; Kothari, C; Patel, C; Patel, R; Solanki, R; Wadhwana, P | 1 |
6 review(s) available for glipizide and metformin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Combination agents for diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glipizide; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Treatment Outcome | 2012 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds | 2018 |
Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Gliclazide; Glipizide; Glucagon-Like Peptide-1 Receptor; Glyburide; History, 20th Century; History, 21st Century; Humans; Hypoglycemic Agents; Insulin Secretion; Insulin-Secreting Cells; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Failure | 2019 |
Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glipizide; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2022 |
33 trial(s) available for glipizide and metformin
| Article | Year |
|---|---|
Glipizide in the treatment of maturity-onset diabetes: a multi-centre, out-patient study.
Topics: Adult; Aged; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Female; Glipizide; Glycosuria; Humans; Male; Metformin; Middle Aged; Phenformin; Sulfonylurea Compounds; Time Factors | 1978 |
Insulin and sulphonylurea in the therapy of type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Metformin; Middle Aged; Placebos; Random Allocation; Sulfonylurea Compounds | 1990 |
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Glycated Hemoglobin; Hexosamines; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Treatment Failure; Triglycerides | 1995 |
Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue.
Topics: Adipose Tissue; Blood Glucose; Circadian Rhythm; Cohort Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glipizide; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Single-Blind Method; Time Factors | 1997 |
Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
Topics: Adult; Aged; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes.
Topics: Blood Glucose; Brachial Artery; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nitroglycerin; Time Factors; Treatment Outcome; Ultrasonography | 2001 |
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glipizide; Humans; Hypoglycemic Agents; Insulin; Metformin; Obesity; Placebos; Sulfonylurea Compounds; Triglycerides; Weight Loss | 2001 |
Improved glucose control decreases the interaction of plasma low-density lipoproteins with arterial proteoglycans.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Female; Fructosamine; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins, LDL; Male; Metformin; Middle Aged; Proteoglycans | 2002 |
Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fibrinolysis; Glipizide; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Research Design | 2002 |
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2003 |
Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study.
Topics: Administration, Oral; Adult; Aorta; Blood Flow Velocity; Blood Glucose; Blood Pressure; Double-Blind Method; Glipizide; Glucose Tolerance Test; Heart Ventricles; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Metformin; Middle Aged; Prospective Studies | 2005 |
Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM.
Topics: Blood Glucose; Chemistry, Pharmaceutical; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Male; Metformin; Middle Aged | 2005 |
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.
Topics: Administration, Oral; Adult; Blood Proteins; Drug Interactions; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oligoribonucleotides; Protein Binding; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2006 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice.
Topics: Administration, Oral; Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Follow-Up Studies; Glipizide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin, Isophane; Insulin, Long-Acting; Metformin; Middle Aged | 2007 |
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2010 |
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2010 |
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Weight Gain | 2011 |
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Glipizide; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glipizide; Humans; Male; Metformin; Middle Aged | 2013 |
[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Topics: Aged; Balanitis; Benzhydryl Compounds; Blood Glucose; Body Weight; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glipizide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2013 |
Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dizziness; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Headache; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Piperidines; Prospective Studies; Treatment Outcome; Triglycerides; Uracil; Weight Gain | 2013 |
Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2013 |
The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Treatment Outcome | 2013 |
Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2014 |
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2014 |
Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glipizide; Humans; Lipids; Male; Metabolome; Metabolomics; Metformin; Middle Aged | 2014 |
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pancreatitis; Piperidines; Treatment Outcome; Uracil | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Metformin; Risk Factors | 2014 |
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.
Topics: Adult; Aged; Alleles; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Glipizide; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Transcription Factor 7-Like 2 Protein; Treatment Outcome | 2015 |
Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Endpoint Determination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Treatment Outcome; Uracil; Weight Gain; Young Adult | 2016 |
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Fibroblast Growth Factors; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2022 |
61 other study(ies) available for glipizide and metformin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of bed time intermediate acting insulin in NIDDM subjects refractory to a combination of sulphonylureas and biguanides.
Topics: Biguanides; Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Injections, Subcutaneous; Insulin, Long-Acting; Lipids; Male; Metformin; Middle Aged; Phenformin; Sulfonylurea Compounds; Time Factors | 1992 |
Grinspan's syndrome: a drug-induced phenomenon?
Topics: Aged; Aged, 80 and over; Atenolol; Bendroflumethiazide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Female; Furosemide; Glipizide; Humans; Hypertension; Lichen Planus; Metformin; Middle Aged; Mouth Diseases; Spironolactone; Syndrome | 1990 |
Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes.
Topics: Adult; Aged; Blood Glucose; Calcium; Diabetes Mellitus, Type 2; Female; Glipizide; Homeostasis; Humans; Longitudinal Studies; Magnesium; Male; Metformin; Middle Aged; Sulfonylurea Compounds | 1988 |
[Effects of treatment with glipizide-metformin on the behavior of blood sugar, insulin and lipids after intravenous administration of glucose in diabetic subjects].
Topics: Adult; Blood Glucose; Diabetes Mellitus; Female; Glipizide; Glucose; Humans; Insulin; Lipids; Male; Metformin; Middle Aged; Sulfonylurea Compounds | 1974 |
Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.
Topics: Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Food; Glipizide; Humans; Insulin; Intestinal Mucosa; Lipoproteins; Male; Metformin; Middle Aged; Risk Factors; Triglycerides | 1994 |
A retrospective analysis of the efficacy and safety of metformin in the African-American patient.
Topics: Adult; Aged; Aged, 80 and over; Black People; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin, Isophane; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies | 1997 |
[Impact of intensive blood glucose control with hypoglycemic sulfamides, metformin or insulin on complications of non-insulin dependent diabetes].
Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 2; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors | 1999 |
A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.
Topics: Acarbose; Decision Trees; Diabetes Mellitus, Type 2; Drug Costs; Glipizide; Health Care Costs; Health Resources; Humans; Hypoglycemic Agents; Managed Care Programs; Markov Chains; Metformin; Monte Carlo Method; Office Visits; Trisaccharides; United States | 1999 |
Serum insulin assay: an important therapeutic tool in management of freshly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glipizide; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Treatment Outcome; Triglycerides | 2000 |
ION-pair liquid chromatography technique for the estimation of metformin in its multicomponent dosage forms.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Gliclazide; Glipizide; Hypoglycemic Agents; Metformin; Quality Control; Reference Standards; Reproducibility of Results | 2001 |
Metaglip and Avandamet for type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fees, Pharmaceutical; Glipizide; Humans; Hypoglycemic Agents; Metformin; Thiazoles | 2002 |
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
Topics: Carbamates; Cohort Studies; Decision Trees; Diabetes Mellitus, Type 2; Direct Service Costs; Drug Costs; Drug Therapy, Combination; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Managed Care Programs; Markov Chains; Metformin; Models, Economic; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2003 |
Retrobulbar injection of methylprednisolone in diffuse diabetic macular edema.
Topics: Administration, Oral; Aged; Aged, 80 and over; Diabetes Mellitus; Diabetic Retinopathy; Glipizide; Glucocorticoids; Humans; Injections; Macular Edema; Metformin; Methylprednisolone; Middle Aged; Orbit; Visual Acuity | 2004 |
The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma.
Topics: Chromatography, High Pressure Liquid; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Metformin; Reference Standards; Sensitivity and Specificity | 2005 |
Design and evaluation of compound metformin/glipizide elementary osmotic pump tablets.
Topics: Delayed-Action Preparations; Diabetes Mellitus; Drug Design; Glipizide; Humans; Hypoglycemic Agents; Metformin; Osmotic Pressure; Solubility | 2005 |
In vitro and in vivo evaluation of two extended release preparations of combination metformin and glipizide.
Topics: Animals; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dogs; Drug Combinations; Glipizide; Hypoglycemic Agents; Intestinal Absorption; Metformin; Osmosis; Solubility; Tablets | 2005 |
Toxicology case of the month: oral hypoglycaemic overdose.
Topics: Adolescent; Drug Overdose; Emergency Service, Hospital; Female; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Risk Assessment; Treatment Outcome; Western Australia | 2006 |
Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Glipizide; Humans; Male; Metformin; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2007 |
Larval zebrafish as a model for glucose metabolism: expression of phosphoenolpyruvate carboxykinase as a marker for exposure to anti-diabetic compounds.
Topics: Animals; Blood Glucose; Cyclic AMP; Dexamethasone; Glipizide; Hypoglycemic Agents; Larva; Metformin; Models, Animal; Phosphoenolpyruvate Carboxykinase (GTP); Rosiglitazone; Thiazolidinediones; Tretinoin; Zebrafish | 2007 |
Pioglitazone: an anti-diabetic compound with anti-aging properties.
Topics: Animals; Basal Metabolism; Dose-Response Relationship, Drug; Drosophila melanogaster; Fertility; Glipizide; Hypoglycemic Agents; Insulin; Longevity; Metformin; Models, Biological; Pioglitazone; Population Density; Research Design; Rosiglitazone; Sexual Behavior, Animal; Signal Transduction; Thiazolidinediones; Time Factors | 2007 |
Clinical decisions. Management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glipizide; Glucagon-Like Peptide 1; Humans; Hypertension; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Obesity; Pioglitazone; Thiazolidinediones | 2008 |
[Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry].
Topics: Administration, Oral; Chromatography, Liquid; Glipizide; Humans; Hypoglycemic Agents; Male; Metformin; Sensitivity and Specificity; Tandem Mass Spectrometry; Young Adult | 2007 |
Clinical decisions. Management of type 2 diabetes--polling results.
Topics: Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin, Isophane; Metformin; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2008 |
Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Triazoles | 2008 |
Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release.
Topics: Chemistry, Pharmaceutical; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Excipients; Glipizide; Hypoglycemic Agents; Hypromellose Derivatives; Metformin; Methylcellulose; Sodium Dodecyl Sulfate; Tablets; Technology, Pharmaceutical; Viscosity | 2008 |
Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; France; Glipizide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Stress, Psychological; Sulfonylurea Compounds | 2008 |
Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
Topics: Adult; Case-Control Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Risk; Sulfonylurea Compounds | 2008 |
In vitro and in vivo acute antihyperglycemic effects of five selected indigenous plants from Jordan used in traditional medicine.
Topics: Achillea; alpha-Amylases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Ethnopharmacology; Female; Glipizide; Glucan 1,4-alpha-Glucosidase; Glucose Intolerance; Humans; Hypoglycemic Agents; In Vitro Techniques; Jordan; Medicine, Arabic; Metformin; Phytotherapy; Pistacia; Plant Extracts; Plants, Medicinal; Rats; Rats, Sprague-Dawley; Rheum; Rosaceae; Starch; Teucrium | 2011 |
Inlay osmotic pump tablets containing metformin and glipizide.
Topics: Chemistry, Pharmaceutical; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Drug Delivery Systems; Glipizide; Humans; Hypoglycemic Agents; Metformin; Osmosis; Particle Size; Solubility; Tablets | 2011 |
The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Risk Factors; Sulfonylurea Compounds | 2012 |
Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.
Topics: Adamantane; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality-Adjusted Life Years | 2012 |
Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Propensity Score; Retrospective Studies; Sulfonylurea Compounds; Young Adult | 2012 |
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Topics: Adult; Aged; Aged, 80 and over; Calibration; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Time Factors; Triazoles | 2012 |
Simultaneous quantification of metformin and glipizide in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Topics: Adult; Chromatography, High Pressure Liquid; Drug Stability; Glipizide; Humans; Linear Models; Male; Metformin; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Young Adult | 2013 |
Rapid extraction, identification and quantification of oral hypoglycaemic drugs in serum and hair using LC-MS/MS.
Topics: Acetonitriles; Chromatography, Liquid; Female; Forensic Toxicology; Gliclazide; Glipizide; Glyburide; Hair; Humans; Hypoglycemic Agents; Limit of Detection; Male; Mass Spectrometry; Metformin; Methanol; Middle Aged; Molecular Structure; Solvents; Sulfonylurea Compounds | 2012 |
[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glipizide; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2013 |
Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; United States; Veterans | 2013 |
Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus.
Topics: Aged; Amino Acids, Aromatic; Amino Acids, Branched-Chain; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Spectrum Analysis | 2013 |
Comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes care 2013;36:1304-1311.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Male; Metformin | 2014 |
Response to comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes care 2013;36:1304-1311.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Male; Metformin | 2014 |
Hypoglycemia, its implications in clinical practice, and possible ways to prevent it.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Glipizide; Humans; Hypoglycemia; Male; Metformin | 2014 |
Disseminated cryptococcosis in a diabetic patient.
Topics: Administration, Oral; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Fluconazole; Glipizide; Humans; Hypoglycemic Agents; Immunocompromised Host; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Morbidity; Myocardial Infarction; Piperidines; Registries; Retrospective Studies; Risk Factors; Stroke; Sulfonylurea Compounds; Tolbutamide | 2015 |
Antiglycation and cell protective actions of metformin and glipizide in erythrocytes and monocytes.
Topics: Antioxidants; Cytoprotection; Diabetes Mellitus; Erythrocytes; Glipizide; Glycated Serum Albumin; Glycation End Products, Advanced; Glycosylation; Humans; Metformin; Monocytes; Native Polyacrylamide Gel Electrophoresis; Oxidative Stress; Pyruvaldehyde; Serum Albumin; Serum Albumin, Bovine | 2016 |
Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade.
Topics: AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoates; Blotting, Western; Cardiotonic Agents; Cells, Cultured; Endothelium, Vascular; Glipizide; Humans; Male; MAP Kinase Signaling System; Metformin; Metoprolol; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Rats, Inbred SHR; Rats, Inbred WKY; Real-Time Polymerase Chain Reaction; Telmisartan | 2016 |
Simultaneous Determination of Metformin, Glipizide, Repaglinide, and Glimepiride or Metformin and Pioglitazone by a Validated LC Method: Application in the Presence of Metformin Impurity (1-Cyanoguanidine).
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Contamination; Glipizide; Guanidines; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Synchronized and controlled release of metformin hydrochloride/glipizide from elementary osmotic delivery.
Topics: Biological Availability; Cellulose; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Glipizide; Hypoglycemic Agents; Metformin; Osmosis; Solubility; Tablets | 2017 |
Topics: Adult; Aged; Alleles; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotyping Techniques; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Male; Metformin; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Retrospective Studies; Risk Factors; Sulfonylurea Compounds; Transcription Factor 7-Like 2 Protein | 2018 |
Sensitive detection of antidiabetic compounds and one degradation product in wastewater samples by a new SPE-LC-MS/MS method.
Topics: Chromatography, Liquid; Environmental Monitoring; Gliclazide; Glipizide; Glyburide; Hypoglycemic Agents; Metformin; Reproducibility of Results; Solid Phase Extraction; Sulfonylurea Compounds; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical | 2021 |
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Carbamates; Databases, Factual; Diabetes Mellitus, Type 2; Drug Interactions; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Medicaid; Metformin; Middle Aged; Nateglinide; Pharmacoepidemiology; Piperidines; Secretagogues; Sulfonylurea Compounds; United States | 2022 |
Spectrophotometric Determination of Metformin in Different Pharmaceutical Combinations With Glipizide or Sitagliptin in Presence of Toxic Impurities of Metformin.
Topics: Glipizide; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Tablets | 2022 |
Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Metformin; Nitrosamines; Pharmaceutical Preparations; Tandem Mass Spectrometry | 2023 |